Ipsen announces late-breaking data from first head-to-head study comparing Dysport® and Botox® in adults with upper limb spasticity
· Financial Post
PARIS, FRANCE – 19 MAY 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced today results from the only prospective, head-to-head Phase IV DIRECTION trial comparing Dysport® (abobotulinumtoxinA) to Botox® (onabotulinumtoxinA) in adults living with upper limb spasticity (ULS)1 will be presented as a late-breaking presentation at the International Society of Physical and Rehabilitation Medicine (ISPRM) world congress in Vancouver on May 19, 2026. The trial showed that patients treated with Dysport had a non-inferior safety profile to Botox and achieved longer-lasting symptom control (based on a pre-specified 80% confidence interval)1. Read More
Visit tr-sport.click for more information.